Fluticasone furoate nasal spray reduces the nasal-ocular reflex: A mechanism for the efficacy of topical steroids in controlling allergic eye symptoms

Journal of Allergy and Clinical Immunology

Volumn 123, Issue 6, 2009, Pages 1342-1348

  Baroody, Fuad M ^a   Shenaq, Deanna ^a   DeTineo, Marcy ^a   Wang, JiangHong ^a   Naclerio, Robert M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Allergic rhinoconjunctivitis; eosinophils; fluticasone furoate nasal spray; nasal challenge; nasal ocular reflex; priming

Indexed keywords

ALLERGEN; ANTIGEN; FLUTICASONE FUROATE; HISTAMINE; PLACEBO; STEROID; ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT;

ADULT; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EYE DISEASE; FEMALE; HISTAMINE RELEASE; HUMAN; MALE; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; REFLEX; SNEEZING; STEROID THERAPY; SYMPTOM; TREATMENT OUTCOME; DRUG EFFECT; EOSINOPHIL; EYE; HAY FEVER; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; NOSE; NOSE PROVOCATION TEST; PATHOLOGICAL REFLEX; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADMINISTRATION, INTRANASAL; ADULT; ALLERGENS; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EOSINOPHILS; EYE; FEMALE; HUMANS; MALE; NASAL PROVOCATION TESTS; NOSE; REFLEX, ABNORMAL; RHINITIS, ALLERGIC, SEASONAL;

EID: 67649158583     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.03.015     Document Type: Article

References (28)

1. Baroody F.M. Allergic rhinitis: broader disease effects and implications for management. Otolaryngol Head Neck Surg 128 (2003) 616-631
2. Goetzel R.Z., Long S.R., Ozminkowski R.J., Hawkins K., Wang S., and Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med 46 (2004) 398-412
3. Fineman S. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol 88 (2002) S2-S7
4. Blaiss M. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 83 (1999) 449-454
5. Craig T.J., McCann J.L., Gurevich F., and Davies M.J. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 114 (2004) S139-S145
6. Van Strien R.T., Engel R., and Holst O. Microbial exposure of rural school children as assessed by levels of N-acetly-muramic acid. J Allergy Clin Immunol 113 (2004) 860-867
7. Wuthrich B., Brignoli R., Canevascini M., and Gerber M. Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 128 (1998) 139-143
8. Allergies in America: a landmark survey of nasal allergy sufferers: executive summary. Available at:. http://www.myallergiesinamerica.com/
9. Allergies in America: a landmark survey of nasal allergy sufferers: executive summary. Available at: (2008), Sepracor Inc, Marlborough
10. Noon L. Prophylactic inoculation against hay fever. Lancet 1 (1911) 1572-1573
11. Baroody F.M., Foster K., Markarian A., DeTineo M., and Naclerio R.M. Nasal ocular reflexes and eye symptoms in patients with allergic rhinitis. Ann Allergy Asthma Immunol 100 (2008) 194-199
12. Connell J.T. Quantitative intranasal pollen challenge, III: the priming effect in allergic rhinitis. J Allergy 43 (1969) 33-44
13. Wachs M., Proud D., Lichtenstein L.M., Kagey-Sobotka A., Norman P.S., and Naclerio R.M. Observations on the pathogenesis of nasal priming. J Allergy Clin Immunol 84 (1989) 492-501
14. Allen D.B. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 106 (2000) S179-S190
15. Weiner J., Abramson M., and Puy R. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised rontrolled trials. BMJ 317 (1998) 1624-1629
16. Baroody F.M., Ford S., Lichtenstein L.M., Kagey-Sobotka A., and Naclerio R.M. Physiologic responses and histamine release after nasal antigen challenge: effect of atropine. Am J Respir Crit Care Med 149 (1994) 1457-1465
17. Pipkorn U., Proud D., Lichtenstein L.M., Kagey-Sobotka A., Norman P.S., and Naclerio R.M. Inhibition of mediator release in allergic rhinitis by pretreatment with topical glucocorticosteroids. N Engl J Med 316 (1987) 1506-1510
18. Baroody F.M., Ford S., Proud D., Kagey-Sobotka A., Lichtenstein L.M., and Naclerio R.M. Relationship between histamine and physiological changes during the early response to nasal antigen provocation. J Appl Physiol 86 (1999) 659-668
19. Wagenmann M., Baroody F.M., Cheng C.C., Kagey-Sobotka A., Lichtenstein L.M., and Naclerio R.M. Bilateral increases in histamine after unilateral nasal allergen challenge. Am J Respir Crit Care Med 155 (1997) 426-431
20. Malmberg H., Binder E., Fraki J., Harvima I., Salo O., and Holopainen E. Nasal reactions elicited by unilateral allergen challenge. Acta Otolaryngol 107 (1989) 446-449
21. Konno A., and Togawa K. Role of the vidian nerve in nasal allergy. Ann Otol Rhinol Laryngol 88 2 Pt 1 (1979) 258-266
22. Raphael G.D., Igarashi Y., White M.V., and Kaliner M.A. The pathophysiology of rhinitis, V: sources of protein in allergen-induced nasal secretions. J Allergy Clin Immunol 88 (1991) 33-42
23. Denburg J.A., Dolovich J., and Harnish D. Basophil mast cell and eosinophil growth and differentiation factors in human allergic disease. Clin Exp Allergy 19 (1989) 249-254
24. DeWester J., Philpot E.E., Westlund R.E., Cook C.K., and Rickard K.A. The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 24 (2003) 331-337
25. Spangler D.L., Abelson M.B., Ober A., and Gotnes P.J. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin Ther 25 (2003) 2245-2267
26. Mygind N., Nielsen L.P., Hoffmann H.J., et al. Mode of action of intranasal corticosteroids. J Allergy Clin Immunol 108 (2001) S16-S25
27. Bielory L. Ocular symptom reduction in patients with seasonal allergic rhinitis treated with the intranasal corticosteroid mometasone furoate. Ann Allergy Asthma Immunol 100 (2008) 272-279
28. Naclerio R.M. Intranasal corticosteroids reduce ocular symptoms associated with allergic rhinitis. Otolaryngol Head Neck Surg 138 (2008) 129-139